亚太药业迎医药业内新主，邱中勋执掌，创新药战略迎来强协同

Group 1 - Zhejiang Apac Pharmaceutical Co., Ltd. announced the transfer of 108,945,566 shares, representing 14.61% of its total equity, from its controlling shareholder to Zhejiang Xinghao Holdings, making Xinghao the new controlling shareholder [1] - The pharmaceutical industry is experiencing frequent changes in control, driven by policy and market pressures, leading to a deep reshuffle [2] - The industry is expected to see a polarization, with large pharmaceutical companies with strong R&D capabilities leading, while specialized companies, particularly innovative drug firms, will capture market share [2] Group 2 - The new controlling shareholder, Mr. Qiu Zhongxun, has a strong pharmaceutical background and is the actual controller of the successful digital pharmaceutical platform, Yaodou Technology, which has maintained profitability since 2019 and surpassed 6 billion yuan in revenue in 2024 [3] - Yaodou Technology has extensive partnerships with nearly 1,000 pharmaceutical companies and a trading scale exceeding 65 billion yuan, providing significant resources for Apac Pharmaceutical [3] - The collaboration with Yaodou Technology is expected to enhance Apac Pharmaceutical's commercialization of innovative products and improve operational efficiency, with expectations for strategic breakthroughs in the innovative drug sector [3]